Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 8/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 8/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 8/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 8/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.42 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.42 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.42 |
| ▸ | GRIK4 | Q16099 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4704409 | 0.82 | GRIA1 (0.64) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL9091900 | 0.79 | GRIA1 (0.40) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL9364670 | 0.78 | CA12 (0.43) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL462740 | 0.76 | GRIN2D (0.61) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL9365102 | 0.75 | DAO (0.36) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL9365335 | 0.73 | GRIA1 (0.45) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL9826888 | 0.73 | CA12 (0.56) | CA12CA9DAO | |
| SCHEMBL9080167 | 0.73 | CA12 (0.52) | CA12CA9DAO | |
| SCHEMBL9395793 | 0.70 | CA12 (0.53) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL9364598 | 0.70 | DAO (0.70) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0377112-B1 | Quinoxaline compounds and their preparation and use | NOVO NORDISK AS (DK) | 1994-08-24 | — | — | EP | claimed |
| US-5061706-A | 2,3-QUINOXALINEDIONES FOR USE AS NEUROLEPTICS | NOVO NORDISK A/S (DK) | 1991-10-29 | — | — | US | claimed |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2025-09-18 | — | — | US | disclosed |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | PARIS SCIENCES ET LETTRES (FR) | 2025-06-03 | — | — | US | disclosed |
| CN-111386107-A | Use of probenecid in the treatment of an epileptic disease, disorder or condition | 巴黎科技与文学─拉丁区 | 2020-07-07 | — | — | CN | disclosed |
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2020-05-28 | — | — | US | disclosed |
| EP-3651758-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019012109-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2019-01-17 | — | — | WO | disclosed |
| EP-0377112-B1 | Quinoxaline compounds and their preparation and use | NOVO NORDISK AS (DK) | 1994-08-24 | — | — | EP | disclosed |
| US-5061706-A | 2,3-QUINOXALINEDIONES FOR USE AS NEUROLEPTICS | NOVO NORDISK A/S (DK) | 1991-10-29 | — | — | US | disclosed |
| EP-0377112-A1 | Quinoxaline compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1990-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | GRIA1 346/4885GRIA2 127/4885GRIA3 170/4885 |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | GRIA1 346/4885GRIA2 127/4885GRIA3 170/4885 |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | NLN, CLN6, SLC1A2 | GRIA1 346/4885GRIA2 127/4885GRIA3 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.